Numerous biotech firms, from top-rated Catalyst Ph
Post# of 25481
(Total Views: 408)
Posted On: 09/22/2022 9:28:57 AM
Numerous biotech firms, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a fresh bull market despite the faltering stock market. The unexpected success of the biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability.
Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.
Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.
Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.
The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.
Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.
Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.
Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.
The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.
Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
(0)
(0)